BEIJING

北京

,

，

July 8, 2025

2025年7月8日

/PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq:

/PRNewswire/ -- 莱克希尔生物制药有限公司（纳斯达克：

LSB

最低有效位

) (the 'Company'), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has entered into a share and warrant purchase agreement (the 'Purchase Agreement') with an institutional investor for the issuance and sale of 16,987,542 ordinary shares of the Company, par value .

)（“公司”），一家全球生物制药公司，致力于发现、开发、生产和交付新一代疫苗和治疗性生物制品以应对传染病和癌症，今天宣布已与一家机构投资者达成股份和认股权证购买协议（“购买协议”），将发行和出售16,987,542股公司普通股，票面价值。

US$0.0002

0.0002美元

per share, at

每股，于

US$0.883

0.883美元

per share, and 16,987,542 warrants, each entitling the institutional investor to purchase one ordinary share at an exercise price of

每股，以及16,987,542份认股权证，每份认股权证赋予机构投资者以行权价格购买一股普通股的权利。

US$1.079

1.079美元

at any time and from time to time during a 36-month period, in a private placement of

在36个月期间内，随时以及不时地，在私募中

US$15 million

1500万美元

exempt from registration pursuant to Regulation S under the Securities Act of 1933, as amended. The closing of the private placement is expected to take place as soon as possible upon agreement by the parties to the Purchase Agreement, subject to customary conditions precedent stipulated thereunder..

根据修订后的1933年《证券法》S条例，豁免注册。私募的完成预计将在双方就《购买协议》达成一致后尽快进行，但需满足该协议中规定的惯常先决条件。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation, or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约或购买要约的邀请，也不得在任何州或司法管辖区进行这些证券的销售，因为在这些州或司法管辖区，此类要约、邀请或证券销售在根据任何此类州或司法管辖区的证券法进行注册或资格认证之前是非法的。

Safe Harbor Statement

安全港声明

This press release contains 'forward-looking statements'' within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of the Company, the development progress of all product candidates, the progress and results of all clinical trials, the Company's ability to source and retain talent, and the cash position of the Company.

本新闻稿包含根据修订后的1933年《证券法》第27A条、修订后的1934年《证券交易法》第21E条以及1995年《私人证券诉讼改革法》所定义的“前瞻性声明”。本新闻稿中除历史或当前事实陈述之外的所有陈述均为前瞻性声明，包括但不限于关于公司预期增长、所有候选产品开发进展、所有临床试验的进展和结果、公司吸引和留住人才的能力以及公司现金状况的陈述。

Forward-looking statements may be identified by the use of words such as 'estimate,' 'plan,' 'project,' 'forecast,' 'intend,' 'will,' 'expect,' 'anticipate,' 'believe,' 'seek,' 'target,' or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters.

前瞻性声明可以通过使用诸如“估计”、“计划”、“预测”、“打算”、“将”、“预期”、“预计”、“相信”、“寻求”、“目标”或其他类似的词语来识别，这些词语预测或指示未来事件或趋势，或者不是关于历史事实的陈述。

These statements are based on various assumptions, whether identified in this press release, and on the current expectations of the Company's management and are not predictions of actual performance..

这些声明基于各种假设，无论是否在本新闻稿中提及，并且基于公司管理层的当前预期，并非对实际业绩的预测。

The Company cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including those included under the heading 'Risk Factors' in the Company's most recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC.

公司无法向您保证本新闻稿中的前瞻性陈述将被证明是准确的。这些前瞻性陈述受到若干风险和不确定性的影响，包括公司最近一份20-F表年度报告中“风险因素”标题下包含的内容，以及公司在随后向美国证券交易委员会（SEC）提交的文件中讨论的潜在风险、不确定性和其他重要因素。

There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.

可能还存在公司目前尚未知晓的或公司目前认为不重要的其他风险，这些风险也可能导致实际结果与前瞻性陈述中包含的结果不同。鉴于这些前瞻性陈述中存在重大不确定性，本新闻稿中的任何内容均不应被视为任何人对本文所述的前瞻性陈述将会实现或此类前瞻性陈述的任何预期结果将会实现的保证。

The forward-looking statements in this press release represent the views of the Company as of the date of this press release. Subsequent events and developments may cause those views to change. However, while the Company may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law.

本新闻稿中的前瞻性陈述仅代表公司截至本新闻稿发布日期的观点。后续事件和发展可能导致这些观点发生变化。然而，尽管公司未来可能会更新这些前瞻性陈述，但目前无意这样做，除非适用法律要求。

You should, therefore, not rely on these forward-looking statements as representing the views of the Company as of any date subsequent to the date of this press release. Except as may be required by law, the Company does not undertake any duty to update these forward-looking statements..

因此，您不应依赖这些前瞻性陈述来代表公司自本新闻稿发布日期之后的任何日期的观点。除非法律要求，公司没有义务更新这些前瞻性陈述。

SOURCE LakeShore Biopharma Co., Ltd.

来源：湖岸生物制药有限公司

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用